Want to see JP:4565 full AI Analyst Report?
4565 Stock Chart & Stats
¥862.00
-¥10.00(-0.99%)
At close: 4:00 PM EST
¥862.00
-¥10.00(-0.99%)
Day’s Range― - ―
52-Week Range¥723.00 - ¥1,247.00
Previous CloseN/A
Volume458.60K
Average Volume (3M)945.56K
Market Cap
¥84.19B
Enterprise Value¥135.51K
Total Cash (Recent Filing)¥11.60B
Total Debt (Recent Filing)¥55.83B
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 07, 2026EPS Estimate
-3.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-110.53
Shares Outstanding92,614,160
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44.45
Revenue Forecast (FY)¥40.43B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSosei's consistent TTM revenue growth (~+15.6%) indicates expanding demand for its discovery services and partnered programs. Durable growth supports longer-term deal flow, strengthens partner credibility, and builds a pipeline that can trigger milestone and royalty payments over multiple quarters.
High Gross MarginSustained gross margins near 72% reflect high-value, scalable discovery work and IP monetization. High underlying margins create operating leverage potential: as revenue from partnerships and milestones grows, incremental profitability can improve materially without proportional cost increases.
Collaboration-Driven Business ModelA partnership-first model (upfronts, R&D services, milestones, royalties) reduces commercialization risk and leverages partner resources. This structurally diversifies revenue sources, can provide non-dilutive funding, and ties Sosei's upside to multiple external development paths over time.
Bears Say
Sustained LossesMaterial negative EBIT and a ~-42% net margin indicate ongoing unprofitable operations. Persistent losses erode retained capital, increase reliance on external financing, and limit the company's ability to self-fund R&D or scale internal programs without dilutive raises or restrictive financing terms.
Negative Cash Flow / Cash BurnNegative operating and free cash flow show the business is not self-sustaining and is burning cash. This elevates refinancing and execution risk: if partner payments or capital markets tighten, development timelines and milestone attainment could be delayed or curtailed.
Moderate-to-High Leverage For A Loss-Making BiotechA debt-to-equity ratio near 0.94 is relatively high for a biotech still posting losses. Leverage increases interest and refinancing burdens, reduces financial flexibility, and raises the probability that future growth must be funded by dilutive equity or restrictive debt, pressuring long-term returns.
Sosei Group News
4565 FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was ¥723.00 and its highest was ¥1247.00 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is ¥84.19B.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 15 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on May 01, 2026. The company reported ¥19.82 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of ¥2.5 which represents an annual dividend yield of N/A. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate is -3.53.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 92,614,160 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of ¥19.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.957%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in JP:4565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Technical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
―
Japan Tissue Engineering Co., Ltd.
―